15 Jun 2024 • The addition of dapagliflozin to standard care did not improve clinical outcomes in critically ill patients with acute organ dysfunction.

• A multicenter, randomized clinical trial was conducted in Brazil, involving participants who were admitted to ICUs with organ dysfunction. They were enrolled between November 22, 2022, and August 30, 2023.

• The participants were randomized into two groups: one receiving 10 mg dapagliflozin (n = 248) and standard care, and the other receiving standard care alone (n = 249).

• The primary outcome measured was a composite of hospital mortality, initiation of kidney replacement therapy, and ICU length of stay. The win ratio of dapagliflozin for the primary outcome was not significant (1.01).

The results showed that dapagliflozin did not improve clinical outcomes. However, the wide confidence intervals could not exclude potential benefits or harms.

Source:JAMA| Read full story